Pages that link to "Q33400871"

The following pages link to Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone (Q33400871):

Displaying 23 items.

• Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites (Q27011795) (← links)
• Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data. (Q30828090) (← links)
• Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma (Q33404348) (← links)
• Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma (Q33404570) (← links)
• The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis (Q33410064) (← links)
• Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). (Q33442039) (← links)
• A Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events (Q37577645) (← links)
• An old drug with a new future: bendamustine in multiple myeloma. (Q38139989) (← links)
• Bendamustine in multiple myeloma (Q38530583) (← links)
• Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. (Q38548134) (← links)
• Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update (Q38642648) (← links)
• Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose? (Q38700745) (← links)
• Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance (Q38896793) (← links)
• Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. (Q39048347) (← links)
• Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. (Q40095723) (← links)
• Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma. (Q41970310) (← links)
• Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure (Q45892519) (← links)
• United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. (Q52841629) (← links)
• Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. (Q52958098) (← links)
• Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. (Q53504691) (← links)
• Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma (Q88105195) (← links)
• Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold (Q88564786) (← links)
• Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study (Q89830053) (← links)